For latest information on South African COVID-19 Resource Portal go to sacoronavirus.co.za
Toggle Bar

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.

Takuva, S., Karuna, S.T., Juraska, M., Rudnicki, E., Edupuganti, S., Anderson, M., De La Grecca, R., Gaudinski, M.R., Sehurutshi, A., Orrell, C. and Naidoo, L., 2022. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes89(4), pp.405-413.


Resistance to Mycobacterium tuberculosis infection among highly TB exposed South African gold miners

Chihota, V.N., Ntshiqa, T., Maenetje, P., Mansukhani, R., Velen, K., Hawn, T.R., Wallis, R., Grant, A.D., Churchyard, G.J. and Fielding, K., 2022. Resistance to Mycobacterium tuberculosis infection among highly TB exposed South African gold miners. PloS one17(3), p.e0265036.


The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk.

Mulenga, H., Fiore-Gartland, A., Mendelsohn, S.C., Penn-Nicholson, A., Mbandi, S.K., Borate, B., Musvosvi, M., Tameris, M., Walzl, G., Naidoo, K. and Churchyard, G., 2022. The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine77, p.103886.


The utility of repeat Xpert MTB/RIF testing to diagnose tuberculosis in HIV-positive adults with initial negative result.

Hanifa, Y., Fielding, K.L., Chihota, V.N., Adonis, L., Charalambous, S., Foster, N., Karstaedt, A., McCarthy, K., Nicol, M.P., Ndlovu, N.T. and Sinanovic, E., 2018. The utility of repeat Xpert MTB/RIF testing to diagnose tuberculosis in HIV-positive adults with initial negative result. Gates Open Research2, pp.22-22.